附近上门

Surgical robotics unicorn is being scooped up by in a $3.4 billion cash deal.

In a issued this morning, pharma giant Johnson & Johnson said it may also pay up to an additional $2.35 billion in contingent payments if Auris meets 鈥渃ertain predetermined鈥� and unspecified milestones.

Follow 附近上门 News on

There was in January that this deal was in the works but there were no numbers announced at that time.

It certainly seems like an impressive exit for San Carlos-based Auris, which has raised a total of $733.3 million since its inception in 2007. Its latest raise was a $220 million Series E in November that was led by . That round lifted Auris鈥檚 valuation to about $2 billion. The company develops robotic technologies for medical applications with a focus on lung cancer. 聽CEO will join Johnson & Johnson once the deal closes.

In its press release, Johnson & Johnson said the buy would help 鈥渁ccelerate鈥� its entry into robotics 鈥渨ith potential for growth and expansion into other interventional applications.鈥� In March 2015, Johnson & Johnson signed an agreement with (then known as Google) to create a robotic-assisted surgical platform.

The global general surgery devices market size was in 2016 and expected to grow at a CAGR (compounded annual growth rate) of 8.5 percent through 2025, according to Grand View Research. In its report, Grand View projected that the medical robotics and computer-assisted devices segment was 鈥渆xpected to grow at the highest growth rate owing to increasing R&D initiatives undertaken for the development of accurate computer-assisted devices.鈥�

Illustration: